Ionis Pharmaceuticals IONS Deferred Tax Assets Capitalized Research And Development Expenses
Deferred Tax Assets Capitalized Research And Development Expenses at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's deferred tax assets capitalized research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's deferred tax assets capitalized research and development expenses?
- Ionis Pharmaceuticals (IONS) reported deferred tax assets capitalized research and development expenses of $233.49M in Q4 2025.
- What does deferred tax assets capitalized research and development expenses mean?
- Future tax benefits created by differences in how R&D costs are reported for tax versus accounting purposes.
- How do you interpret deferred tax assets capitalized research and development expenses?
- Higher levels reflect significant R&D investment that will provide tax shields in future periods.
- How does deferred tax assets capitalized research and development expenses compare across companies?
- Highly relevant for pharmaceutical and biotech companies with heavy R&D spending.